['hiv-1 infection']
['b/f/taf']

        Key Inclusion Criteria:

          -  Currently receiving an antiretroviral regimen of E/C/F/TAF FDC (or emtricitabine
             [FTC]/TDF + 3rd agent if currently or previously participated in Study GS-US-292-1826
             [NCT02616783]) for ≥ 3 months

          -  Documented plasma HIV-1 ribonucleic acid (RNA) < 50 copies/mL during treatment with
             E/C/F/TAF (or FTC/TDF + 3rd agent if currently or previously participated in Study
             GS-US-292-1826 [NCT02616783]) for the last 2 visits preceding the screening visit (or
             undetectable HIV-1 RNA level according to the local assay being used if the limit of
             detection is ≥ 50 copies/mL)

          -  Adequate renal function, an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min
             according to the Cockcroft-Gault formula for creatinine clearance

        Key Exclusion Criteria:

          -  An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior
             to screening

          -  Decompensated cirrhosis (eg, ascites, encephalopathy, or variceal bleeding)

          -  Current alcohol or substance use judged by the investigator to potentially interfere
             with participant study compliance

        Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
      